Teppei Okamoto
Overview
Explore the profile of Teppei Okamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoneyama F, Okamoto T, Hamaya T, Kodama H, Fujita N, Yamamoto H, et al.
Urol Case Rep
. 2025 Mar;
59:102978.
PMID: 40034263
Penile metastases are rare, and metastasis of a gastrointestinal stromal tumor (GIST) to the penis is exceedingly uncommon. An 81-year-old man with a history of duodenal GIST, initially treated with...
2.
Ozaki K, Yamamoto H, Sekine Y, Horiguchi H, Hosogoe S, Mikami J, et al.
Int J Urol
. 2025 Mar;
PMID: 40033773
Objective: We aimed to investigate the impact of skin adverse events (AEs) of enfortumab vedotin (EV) on prognosis in patients with locally advanced or metastatic urothelial carcinoma in real-world practice....
3.
Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T, et al.
Cancer Med
. 2024 Dec;
13(24):e70226.
PMID: 39676240
Objective: We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real-world big data included in The National Database of Health Insurance...
4.
Kato T, Furukawa J, Hinata N, Ueda K, Hara I, Hongo F, et al.
Int J Clin Oncol
. 2024 Nov;
30(1):99-109.
PMID: 39549218
Background: Avelumab + axitinib was approved for advanced renal cell carcinoma (aRCC) in Japan in December 2019. We report long-term real-world outcomes with first-line avelumab + axitinib from the J-DART2...
5.
Miura H, Hatakeyama S, Tabata R, Fujimori D, Kawashima Y, Moriyama S, et al.
Int J Urol
. 2024 Aug;
31(12):1330-1336.
PMID: 39175419
Objectives: The objective of this study is to assess the trends in treatment selection for patients with de novo metastatic castration-sensitive prostate cancer in the era of upfront combination therapy....
6.
Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Mikami T, et al.
Sci Rep
. 2024 Jun;
14(1):13433.
PMID: 38862562
In addition to testosterone, various endocrine hormones, such as dehydroepiandrosterone sulfate (DHEA-S) and estradiol, may be involved in erectile function. However, the role of these sex hormones in the erectile...
7.
Fujita N, Iwane T, Tamura Y, Okamoto T, Yamamoto H, Hatakeyama S, et al.
Int J Urol
. 2024 May;
31(8):869-875.
PMID: 38695270
Objectives: Several systematic reviews and meta-analyses have reported positive relationships between erectile dysfunction (ED) and periodontal disease. However, no study has evaluated the relationships of occlusal support status and the...
8.
Yoneyama F, Okamoto T, Tamura Y, Ishii N, Togashi K, Soma O, et al.
Int Urol Nephrol
. 2024 Jan;
56(6):1803-1810.
PMID: 38216828
Purpose: We assessed the association between oral frailty risk and LUTS among middle-aged and older adults in a community-dwelling population. Methods: This cross-sectional study was conducted among 586 subjects aged ...
9.
Okamoto T, Hatakeyama S, Hamaya T, Matsuura T, Saito M, Nishida H, et al.
J Nephrol
. 2023 Nov;
36(9):2613-2620.
PMID: 37938544
Background: Cardiovascular diseases are still highly prevalent after kidney transplantation. However, little is known about the impact of the timing of rejection episodes on cardiovascular disease. The study aimed to...
10.
Hamaya T, Hatakeyama S, Yoneyama T, Tobisawa Y, Kodama H, Fujita T, et al.
Sci Rep
. 2023 Sep;
13(1):15098.
PMID: 37699969
We aimed to evaluate the humoral response after the second and third doses of SARS-CoV-2 mRNA vaccine in ABO blood type incompatible kidney transplant (KT) recipients treated with rituximab. This...